A year to forget for medtech stocks
The biggest surprise is that there were a handful of risers despite the widespread market turmoil.
Medtech approvals stagnate
Device approvals hit a nine-year low in 2022, as the FDA takes its foot further off the gas.
Few big bangs in a quiet year for medtech mergers
J&J's $17bn swoop for Abiomed accounted for 42% of medtech M&A spend last year.
Eclipse plunges Guardant into darkness
Investors punish the liquid biopsy maker for lacklustre data on its colorectal cancer screen.
The problem with Her2-low testing
Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.
Lantheus gets to the Point in therapeutics
Lantheus goes further into radioligand therapeutics, but the market thinks its latest push shortchanges Point Biopharma.
